Search | Invivogen

EndoFit™ OVA protein

OVA (ovalbumin) for in vivo use

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA

R848 VacciGrade™ - TLR7/8-based Adjuvant

Imidazoquinoline compound | Th1 response

NF-κB response of HEK-Blue™-derived cells to R848

NF-κB and IRF responses of THP1-Dual™-derived cells to R848

Poly(I:C) (HMW) VacciGrade™ - TLR3-based Adjuvant

Polyinosine-polycytidylic acid | Th1 response

Dose-dependent activation of TLR3

ODN 2006 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Human) | Th1 response

Species-driven TLR9 differential responses

NF-κB response induced by ODN 2006

IRF response induced by ODN 2006

ODN 2216 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Human) | Th1 response

Dose-dependent NF-κB response of ODN 2216 in HEK-Blue™ hTLR9 cells

Dose-dependent NF-κB and IRF responses in THP1-Dual™ hTLR9 cells

ODN 1826 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Mouse) | Th1 response

NF-κB response of ODN 1826 in HEK-Blue™-derived cells

NF-κB and IRF responses of ODN 1826 in THP1-Dual™ hTLR9 cells

MPLA-SM VacciGrade™- TLR4-based Adjuvant

Monophosphoryl lipid A | Th1 response

Activation of mouse and human TLR4

Absence of TLR2-activating contaminants

Imiquimod VacciGrade™ (R837) - TLR7-based Adjuvant

Imidazoquinoline compound | Th1 response

NF-κB response of HEK-Blue™-derived cells to imiquimod

NF-κB and IRF responses of HEK-Dual™-derived cells to imiquimod

Flagellin FliC VacciGrade™ - TLR5-based Adjuvant

Recombinant flagellin from S. typhimurium | Th1/Th2 response

Rec FLA-ST dose-dependent activation of TLR5

IFA

Incomplete Freund's adjuvant | Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA

Alhydrogel® adjuvant 2%

Aluminium hydroxide gel | Th2 Response

Antibody responses to OVA with different adjuvants

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with Alhydrogel® adjuvant 2%

AddaVax™

Squalene-Oil-in-water | Th1/Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with AddaVax™

MPLA Synthetic VacciGrade™ - TLR4-based Adjuvant

Synthetic monophosphoryl lipid A | Th1 response

MPLAs dose-dependent activation of TLR4

NexaVant™ VacciGrade™ - TLR3 & dsRNA-based Vaccine Adjuvant

Synthetic double stranded RNA | Th1 response

Molecular weight of NexaVant™ (agarose gel)

TLR3 response HEK-Blue™ hTLR3 cells to NexaVant™

IgG level in serum of mice after intramuscular administration

Antigen-specific T cell responses after NexaVant™ treatment

QS-21 (STIMULON®) VacciGrade™

Saponin vaccine adjuvant - CAS #141256-04-4 & CAS #250643-56-2

QS-21 Chemical Structure

#Inflammasome Ligands

LFn-Rod - Mouse NLRC4 Inflammasome Inducer

T3SS Inner Rod (PrgJ) from S. typhimurium.

Functional validation of LFn-Rod using RAW-derived cells

Murine NLRC4 inflammasome response to LFn-Rod

#Inflammasome Ligands

LFn-Needle - Human NLRC4 Inflammasome Inducer

T3SS Needle from B. thailandensis

Functional validation of LFn-Needle using THP1-derived cells

Human NLRC4 inflammasome response to LFn-Needle

ODN 1018 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Human/mouse) | Th1 response

Murine and human TLR9 activation in HEK-Blue™-derived cells

#Inflammasome Ligands

Val-boroPro - NLRP1 Inflammasome Inducer, DPP8/9 inhibitor

Dipeptide boronic acid

Functional validation of Val-boroPro-induced NLRP1 inflammasome activation

AddaS03™ Adjuvant

Oil-in-water nano-emulsion adjuvant

AddaS03™ Adjuvant composition